

WHAT IS CLAIMED IS:

1. A method of alleviating symptoms of neuropathic conditions comprising the step of administering anti-glutamic acid decarboxylase (anti-GAD) antibody in an amount effective to alleviate symptoms of said neuropathic condition.
- 5           2. The method of claim 1, wherein the neuropathic conditions are selected from the group consisting of autism, multiple sclerosis, Parkinson's disease, attention deficit disorder, diabetic neuropathy and pain neuropathy associated with chemotherapy treatment.
3. The method of claim 1 wherein the anti-GAD antibodies are  
10   monoclonal antibodies.
4. The method of claim 1 wherein the administration step is oral.
5. The method of claim 4 wherein the administration step is sublingual.
6. The method of claim 4 wherein the anti-GAD antibodies are  
15   administered in an enterically protected form.
7. The method of claim 1 wherein the administration step is by injection.
8. The method of claim 7 wherein the administration step is by subcutaneous injection.
- 20           9. The method of claim 1 comprising less than 1.0 mg of anti-GAD antibodies.
10. The method of claim 9 comprising less than 1.0  $\mu\text{g}$  of anti-GAD antibodies.
11. The method of claim 9 comprising from  $1 \times 10^{-6}$  to  $1 \times 10^{-2}$   $\mu\text{g}$   
25   of anti-GAD antibodies.
12. The method of claim 9 comprising from  $1 \times 10^{-5}$  to  $1 \times 10^{-2}$   $\mu\text{g}$  of anti-GAD antibodies.
13. The method of claim 1, wherein the anti-GAD antibody is specific for GAD-65.

**BEST AVAILABLE COPY**

14. The method of claim 1, wherein the anti-GAD antibody is specific for GAD-67.

15. A pharmaceutical composition for administration to a subject for alleviating symptoms of neuropathic conditions comprising less than 1.0 mg of anti-GAD antibodies.

16. The pharmaceutical composition of claim 15 comprising less than 0.1  $\mu\text{g}$  of anti-GAD antibodies.

17. The pharmaceutical composition of claim 15 comprising from  $1 \times 10^{-6}$  to  $1 \times 10^{-2}$   $\mu\text{g}$  of anti-GAD antibodies.

18. The pharmaceutical composition of claim 15 comprising from  $1 \times 10^{-5}$  to  $1 \times 10^{-2}$   $\mu\text{g}$  of anti-GAD antibodies.

19. The pharmaceutical composition of claim 15, wherein the antibodies are specific for GAD-65.

20. The pharmaceutical composition of claim 15, wherein the antibodies are specific for GAD-67.

**BEST AVAILABLE COPY**